指南与共识技术与安全CTPET

淋巴瘤试验的放疗靶区命名:国家临床试验网络组的共识建议

Radiation target nomenclature for lymphoma trials: consensus recommendations from the National Clinical Trials Network groups.
指南 / 共识 · Lancet Haematol · 2024-09-30

针对依赖系统性治疗后影像的当代淋巴瘤放疗靶区缺乏标准化命名的问题,国家临床试验网络组的放疗肿瘤学淋巴瘤领袖于2024年秋季召开论坛并建立标准化命名。命名涵盖受累部位放疗、残留部位放疗和PET导向放疗三类,其中PET导向放疗又细分为三种类型。

要点

  • 受累部位放疗包括化疗前疾病的完整头尾范围,仅考虑轴向解剖变化。
  • 残留部位放疗仅针对化疗后CT解剖肿块。
  • PET导向放疗仅针对PET阳性病变,分为三种亚型。

核心结论

  • 论坛建立了淋巴瘤放疗靶区的标准化命名,包括受累部位放疗、残留部位放疗和PET导向放疗三类,其中PET导向放疗分为PET导向受累部位放疗、PET导向残留部位放疗和PET导向残留PET放疗三种。

研究设计与样本

  • 国家临床试验网络组(NRG Oncology、儿童肿瘤学组、SWOG癌症研究网络、肿瘤学临床试验联盟、东部肿瘤协作组-美国放射学影像网络癌症研究组和加拿大癌症试验组)的放疗肿瘤学淋巴瘤领袖于2024年秋季召开论坛并建立标准化命名。

诊断标准与关键数值

  • 受累部位放疗包括化疗前疾病的完整头尾范围,仅考虑轴向解剖变化。
  • 残留部位放疗仅针对化疗后CT解剖肿块。
  • PET导向受累部位放疗使用化疗前受累疾病部位中治疗后影像仍PET高摄取的上-下方面。
  • PET导向残留部位放疗仅使用化疗后CT解剖残留肿块中包含治疗后影像PET高摄取病变的部分,不排除达到完全代谢缓解的部位。
  • PET导向残留PET放疗仅使用PET高摄取灶,不考虑其周围相应的非PET高摄取CT解剖疾病。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Contemporary lymphoma radiation target volumes that rely on post-systemic therapy imaging do not have standardised nomenclature. A forum of radiation oncology lymphoma leaders from the National Clinical Trials Network groups (NRG Oncology, Children's Oncology Group, SWOG Cancer Research Network, Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, and the Canadian Cancer Trials Group) was convened and established standardised nomenclature for these volumes in the autumn of 2024. Involved-site radiotherapy includes the full cranial-caudal extent of prechemotherapy disease and takes into account axial anatomical changes only. Residual site radiotherapy targets only the postchemotherapy CT-anatomical mass. PET-directed radiotherapy exclusively targets PET-positive disease and includes three types: PET-directed involved site radiotherapy using the superior-inferior aspect of prechemotherapy involved disease sites that remain PET-avid on post-treatment imaging; PET-directed residual site radiotherapy using only the postchemotherapy CT-anatomical residual mass that contains the PET-avid lesion on post-treatment imaging, without excluding sites that had complete metabolic response; and PET-directed residual PET radiotherapy using only the PET-avid focus, irrespective of the corresponding adjacent non-PET-avid CT-anatomical disease surrounding it.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Saifi O, Pinnix CC, Ballas LK, et al. Radiation target nomenclature for lymphoma trials: consensus recommendations from the National Clinical Trials Network groups. Lancet Haematol. 2024. PMID: 39362223. doi:10.1016/S2352-3026(24)00276-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。